{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T12:14:17Z","timestamp":1716552857241},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,18]]},"DOI":"10.7759\/cureus.52521","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T23:06:10Z","timestamp":1705619170000},"source":"Crossref","is-referenced-by-count":1,"title":["Cardiac Tamponade and Duodenal Hemorrhage Caused by Inappropriate Use of Dabigatran in a Patient With End-Stage Renal Failure: A Case Report"],"prefix":"10.7759","author":[{"given":"Marina","family":"Hayashida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Kakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Eizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.004424","article-title":"Dabigatran etexilate: a new oral thrombin inhibitor","volume":"123","author":"Hankey GJ","year":"2011","unstructured":"Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011, 123:1436-50. 10.1161\/CIRCULATIONAHA.110.004424","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0699-z","article-title":"Dabigatran etexilate: a review in nonvalvular atrial fibrillation","volume":"77","author":"Blair HA","year":"2017","unstructured":"Blair HA, Keating GM. Dabigatran etexilate: a review in nonvalvular atrial fibrillation. Drugs. 2017, 77:331-44. 10.1007\/s40265-017-0699-z","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2022.04.007","article-title":"Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2","volume":"80","author":"Yamashita T","year":"2022","unstructured":"Yamashita T, Uchiyama S, Atarashi H, et al.. Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2. J Cardiol. 2022, 80:255-60. 10.1016\/j.jjcc.2022.04.007","journal-title":"J Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele F","year":"2013","unstructured":"Schiele F, van Ryn J, Canada K, et al.. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013, 121:3554-62. 10.1182\/blood-2012-11-468207","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.6.1564","article-title":"Bloody pericardial effusion in patients with cardiac tamponade: is the cause cancerous, tuberculous, or iatrogenic in the 1990s?","volume":"116","author":"Atar S","year":"1999","unstructured":"Atar S, Chiu J, Forrester JS, Siegel RJ. Bloody pericardial effusion in patients with cardiac tamponade: is the cause cancerous, tuberculous, or iatrogenic in the 1990s?. Chest. 1999, 116:1564-9. 10.1378\/chest.116.6.1564","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytx018","article-title":"Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series","volume":"1","author":"Nassif T","year":"2017","unstructured":"Nassif T, Banchs J, Yusuf SW, Mouhayar E. Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series. Eur Heart J Case Rep. 2017, 1:ytx018. 10.1093\/ehjcr\/ytx018","journal-title":"Eur Heart J Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytaa482","article-title":"Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report","volume":"5","author":"Shastri P","year":"2021","unstructured":"Shastri P, Bhuta S, Oostra C, Monroe T. Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report. Eur Heart J Case Rep. 2021, 5:ytaa482. 10.1093\/ehjcr\/ytaa482","journal-title":"Eur Heart J Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30021","article-title":"Hemorrhagic pericardial effusion from apixaban use: case report and literature review","volume":"14","author":"Nasir SA","year":"2022","unstructured":"Nasir SA, Babu Pokhrel N, Baig A. Hemorrhagic pericardial effusion from apixaban use: case report and literature review. Cureus. 2022, 14:e30021. 10.7759\/cureus.30021","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly PA","year":"2014","unstructured":"Reilly PA, Lehr T, Haertter S, et al.. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014, 63:321-8. 10.1016\/j.jacc.2013.07.104","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack CV Jr","year":"2017","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J, et al.. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017, 377:431-41. 10.1056\/NEJMoa1707278","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.070","article-title":"Dabigatran reversal with idarucizumab in patients with renal impairment","volume":"74","author":"Eikelboom JW","year":"2019","unstructured":"Eikelboom JW, van Ryn J, Reilly P, et al.. Dabigatran reversal with idarucizumab in patients with renal impairment. J Am Coll Cardiol. 2019, 74:1760-8. 10.1016\/j.jacc.2019.07.070","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.599626","article-title":"Dabigatran level before reversal can predict hemostatic effectiveness of idarucizumab in a real-world setting","volume":"7","author":"Gendron N","year":"2020","unstructured":"Gendron N, Chocron R, Billoir P, et al.. Dabigatran level before reversal can predict hemostatic effectiveness of idarucizumab in a real-world setting. Front Med (Lausanne). 2020, 7:599626. 10.3389\/fmed.2020.599626","journal-title":"Front Med (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1830","article-title":"Management of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysis","volume":"36","author":"Marino KK","year":"2016","unstructured":"Marino KK, Santiago RA, Dew RB 3rd, Berliner N, Connors JM, Connell NT, Tucker JK. Management of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysis. Pharmacotherapy. 2016, 36:e160-5. 10.1002\/phar.1830","journal-title":"Pharmacotherapy"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5482\/HAMO-17-03-0015","article-title":"Repeated administration of idarucizumab to a patient with dabigatran overdose","volume":"38","author":"Haj\u0161manov\u00e1 Z","year":"2018","unstructured":"Haj\u0161manov\u00e1 Z, \u0160igutov\u00e1 P, Lavi\u010dkov\u00e1 A. Repeated administration of idarucizumab to a patient with dabigatran overdose. Hamostaseologie. 2018, 38:39-42. 10.5482\/HAMO-17-03-0015","journal-title":"Hamostaseologie"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2018.04.025","article-title":"Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab","volume":"121","author":"Hegemann I","year":"2018","unstructured":"Hegemann I, Ganter C, Widmer CC, Becker M, M\u00fcller D, Spahn DR. Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab. Br J Anaesth. 2018, 121:505-8. 10.1016\/j.bja.2018.04.025","journal-title":"Br J Anaesth"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxy008","article-title":"Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury","volume":"76","author":"Sheikh-Taha M","year":"2019","unstructured":"Sheikh-Taha M. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury. Am J Health Syst Pharm. 2019, 76:9-12. 10.1093\/ajhp\/zxy008","journal-title":"Am J Health Syst Pharm"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002392","article-title":"Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk a randomized clinical trial","volume":"94","author":"Choi JY","year":"2015","unstructured":"Choi JY, Kang YJ, Jang HM, et al.. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk a randomized clinical trial. Medicine (Baltimore). 2015, 94:e2392. 10.1097\/MD.0000000000002392","journal-title":"Medicine (Baltimore)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao X","year":"2017","unstructured":"Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017, 69:2779-90. 10.1016\/j.jacc.2017.03.600","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.12.022","article-title":"Long-term clinical outcomes of underdosed direct oral anticoagulants in patients with atrial fibrillation and atrial flutter","volume":"134","author":"Ashraf H","year":"2021","unstructured":"Ashraf H, Agasthi P, Shanbhag A, et al.. Long-term clinical outcomes of underdosed direct oral anticoagulants in patients with atrial fibrillation and atrial flutter. Am J Med. 2021, 134:788-96. 10.1016\/j.amjmed.2020.12.022","journal-title":"Am J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014108","article-title":"Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: The SAGE-AF study","volume":"9","author":"Sanghai S","year":"2020","unstructured":"Sanghai S, Wong C, Wang Z, et al.. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: The SAGE-AF study. J Am Heart Assoc. 2020, 9:e014108. 10.1161\/JAHA.119.014108","journal-title":"J Am Heart Assoc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/224495-cardiac-tamponade-and-duodenal-hemorrhage-caused-by-inappropriate-use-of-dabigatran-in-a-patient-with-end-stage-renal-failure-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:13:07Z","timestamp":1707509587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/224495-cardiac-tamponade-and-duodenal-hemorrhage-caused-by-inappropriate-use-of-dabigatran-in-a-patient-with-end-stage-renal-failure-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.52521","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}